Revolutions Medical Acquires Exclusive Rights To License FDA Approved Breast Biopsy Localization System

Main Category: Breast Cancer
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 26 Apr 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

Revolutions Medical Corporation (OTCBB: RMCP - News) recently signed a worldwide exclusive license with Strategic Product Development (SPD) for an image guided navigation system that incorporates high accuracy breast biopsies system (BBS) to conventional mammography systems which number more than 50,000 globally. This technology has already received 510K clearance by the FDA. BBS facilitates accurate and fast non-palpable lesions and micro calcification localization in the treatment of breast cancer. It is low-cost, standalone stereotactic image-based system which uses data from a pair of mammograms to enable radiologists to accurately position a localization needle or biopsy tool at the location of suspicious abnormalities in the patient's breast. Revolutions Medical believes that the BBS will offer significant advantages for the localization and biopsy of breast abnormalities. The system can also be modified to leverage existing popular biopsy tools. The technology can be used to provide a technology platform for future development including multi-modal breast imaging for the image fusion of MRI and X-Ray images. This represents another step in RevMed's mission statement "To make health care safer and less expensive by developing and marketing new products and tools to the medical industry." The BBS will be modified to use Rev Med's proprietary safety syringe technology as well.

Approximately 4 million diagnostic procedures are performed annually worldwide to evaluate abnormalities detected during mammography screening. RevMed believes that this technology has the potential to be deployed in the vast majority of more than 50,000 mammography machines that are currently in use worldwide, including more than 15,000 in the U.S. This market also represents $400M per year in disposables.

"By leveraging the advantages of our RevVac safety syringe and incorporating them into this new FDA cleared BBS technology; RevMed should be able to bring this new exciting product to the marketplace in the 4th quarter of 2009. In the future, by fusing our RevColor and Rev3D MRI technology with x-ray images, we believe there is a possibility of a multi-modal breast imaging technology, which could dramatically increase the accuracy of the detection of breast cancer," states Ron Wheet, CEO, Revolutions Medical Corporation.

For more information please go to http://www.revolutionsmedical.com or contact investor relations at 843-408-6265.

Safe Harbor

Forward-looking statements made in this release are made pursuant to the "safe-harbor" provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made by Revolutions Medical Corporation are not a guarantee of future performance. This news release includes forward- looking statements, including with respect to the future level of business for the parties. These statements are necessarily subject to risk and uncertainty.

Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Revolutions Medical Corporation, and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, properly price, retain and successfully complete projects, and changes in products and competition.

Source
Revolutions Medical Corporation

• Additional
• References
• Citations